» Articles » PMID: 12579198

Prevention of Virus Transmission to Macaque Monkeys by a Vaginally Applied Monoclonal Antibody to HIV-1 Gp120

Overview
Journal Nat Med
Date 2003 Feb 13
PMID 12579198
Citations 231
Authors
Affiliations
Soon will be listed here.
Abstract

A topical microbicide reduces the probability of virus transmission when applied to the vagina or rectum of a person at risk of sexually acquiring HIV-1 infection. An effective microbicide could significantly reduce the global spread of HIV-1, particularly if women were able to use it covertly to protect themselves. A microbicide could target the incoming virus and either permanently inactivate it or reduce its infectivity, or it could block receptors on susceptible cells near the sites of transmission. We describe here how vaginal administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from simian-human immunodeficiency virus (SHIV) infection through the vagina. Only 3 of 12 animals receiving 5 mg b12 vaginally in either saline or a gel and then challenged vaginally (up to 2 h later) with SHIV-162P4 became infected. In contrast, infection occurred in 12 of 13 animals given various control agents under similar conditions. Lower amounts of b12 were less effective, suggesting that protection was dose dependent. These observations support the concept that viral entry inhibitors can help prevent the sexual transmission of HIV-1 to humans.

Citing Articles

Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.

Symmonds J, Gaufin T, Xu C, Raehtz K, Ribeiro R, Pandrea I Viruses. 2024; 16(6.

PMID: 38932264 PMC: 11209256. DOI: 10.3390/v16060972.


Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure.

Suphaphiphat K, Desjardins D, Lorin V, Dimant N, Bouchemal K, Bossevot L Nat Commun. 2023; 14(1):6224.

PMID: 37803011 PMC: 10558491. DOI: 10.1038/s41467-023-41966-4.


Leveraging South African HIV research to define SARS-CoV-2 immunity triggered by sequential variants of concern.

Bhiman J, Moore P Immunol Rev. 2022; 310(1):61-75.

PMID: 35599324 PMC: 9349367. DOI: 10.1111/imr.13086.


Galectins as potential therapeutic targets in STIs in the female genital tract.

Lujan A, Croci D, Rabinovich G, Damiani M Nat Rev Urol. 2022; 19(4):240-252.

PMID: 35105978 DOI: 10.1038/s41585-021-00562-1.


Immunogenicity Evaluation of N-Glycans Recognized by HIV Broadly Neutralizing Antibodies.

Shivatare S, Cheng T, Cheng Y, Shivatare V, Tsai T, Chuang H ACS Chem Biol. 2021; 16(10):2016-2025.

PMID: 34649433 PMC: 8526942. DOI: 10.1021/acschembio.1c00375.